← Ahmad Masri

Papers by Ahmad Masri

Page 2 · newest first

51. Deglutition-Induced Atrial Fibrillation in a Previously Healthy Adult Male: A Rare Trigger Unmasked After Medication DiscontinuationCureus · 2025
52. Incidence and Outcomes of Atrial Fibrillation and Systolic Dysfunction in Patients Receiving Mavacamten for Obstructive Hypertrophic Cardiomyopathy: A Multicenter Study.2025
53. Safety and Efficacy of Aficamten in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A 96-Week Analysis From FOREST-HCMJournal of Cardiac Failure · 2025
54. Treatment Response to Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy: 96-Week Results From the EXPLORER Cohort of the MAVA–Long-Term Extension Cardiac Magnetic Resonance Imaging SubstudyCirculation · 2025
55. High rate of seroeligibility among MYBPC3-associated hypertrophic cardiomyopathy patients for TN-201, an adeno-associated virus serotype 9 MYBPC3 gene therapyFrontiers in Medicine · 2025
56. A cautionary case series: tafamidis mistreatment following erroneous diagnosis of transthyretin cardiac amyloidosisAmyloid · 2025
57. Cardiopulmonary Exercise Testing for Characterization of Hypertrophic Cardiomyopathy: A Meta‐AnalysisJournal of the American Heart Association · 2025
58. Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic CardiomyopathyNew England Journal of Medicine · 2025
59. eP25 Rate of Negative Histology of the Appendix in Children (Age 8-16 Years)British journal of surgery · 2025
60. WTP3.08 Day Case vs Inpatient Elective SurgeryBritish journal of surgery · 2025
61. Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic CardiomyopathyJournal of the American College of Cardiology · 2025
62. Cardiovascular Hospitalizations Burden Following Septal Myectomy for Obstructive Hypertrophic CardiomyopathyJournal of the American Heart Association · 2025
63. Medical Malpractice Claims for Sports Cardiology Cases Among Young AthletesJACC Advances · 2025
64. Aficamten Treatment for Symptomatic Obstructive Hypertrophic CardiomyopathyJACC Heart Failure · 2025
65. Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trialENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2025
66. Toward a Comprehensive Understanding of Obstructive Hypertrophic CardiomyopathyJACC Basic to Translational Science · 2025
67. Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid CardiomyopathyJournal of the American College of Cardiology · 2025
68. Acoramidis for Transthyretin Amyloid Cardiomyopathy: Open-Label Extension Study Long-Term Follow-UpJournal of Cardiac Failure · 2025
69. Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic CardiomyopathyJACC Heart Failure · 2025
70. Characteristics and Outcomes of Mavacamten Use In 2440 Patients with Obstructive Hypertrophic Cardiomyopathy2025
71. Thermodynamic assessment of hybrid solar-geothermal organic Rankine cycle: An exergy and energy-based analysisEnergy Exploration & Exploitation · 2025
72. Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic CardiomyopathyJournal of the American Heart Association · 2025
73. Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid CardiomyopathyJournal of the American College of Cardiology · 2025
74. Development of Imaging Endpoints for Clinical Trials in AL and ATTR AmyloidosisJACC. Cardiovascular imaging · 2025
75. A Multicenter Study of Contemporary Long-Term Tafamidis Outcomes in Transthyretin Amyloid CardiomyopathyJACC CardioOncology · 2025
76. Optimizing humidification–dehumidification desalination systems: Impact of nozzle position and geometric configuration on performance and efficiencyInternational Journal of Thermofluids · 2025
77. Clinical Phenotype and Prognosis of Asymptomatic Patients With Transthyretin Cardiac Amyloid InfiltrationJAMA Cardiology · 2025
78. Coexisting Calcific Aortic Stenosis and Transthyretin Cardiac Amyloidosis: Real‐World Evaluation of Clinical Characteristics and OutcomesJournal of the American Heart Association · 2025
79. New therapies to treat cardiac amyloidosisCurrent Opinion in Cardiology · 2025
80. The Last Decade in Cardiac AmyloidosisJACC. Cardiovascular imaging · 2025
81. Estimating Meaningful Differences in Measures of Neuropathic Impairment, Health‐Related Quality of Life, and Nutritional Status in Patients With Hereditary Transthyretin AmyloidosisMuscle & Nerve · 2024
82. Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCMJournal of the American College of Cardiology · 2024
83. Aficamten in patients with obstructive hypertrophic cardiomyopathy: an integrated safety analysisEuropean Heart Journal · 2024
84. Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic CardiomyopathyJournal of the American College of Cardiology · 2024
85. Detection of ATTR aggregates in the plasma of polyneuropathic patients with ATTR-V30M amyloidosisAmyloid · 2024
86. National and Regional Medicare Spending on Tafamidis, 2019-2021JAMA Network Open · 2024
87. American Society of Nuclear Cardiology quality metrics for cardiac amyloid radionuclide imagingJournal of Nuclear Cardiology · 2024
88. Aficamten and Cardiopulmonary Exercise Test PerformanceJAMA Cardiology · 2024
89. Mavacamten-Associated Temporal Changes in Left Atrial Function in Obstructive HCMJACC. Cardiovascular imaging · 2024
90. Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathyEuropean Heart Journal · 2024
91. Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic CardiomyopathyJournal of the American College of Cardiology · 2024
92. Serial Changes in Ventricular Strain in Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Insights From the VALOR-HCM TrialCirculation Cardiovascular Imaging · 2024
93. Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trialEuropean Heart Journal · 2024
94. Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic CardiomyopathyJournal of the American College of Cardiology · 2024
95. WP1.18 - A Surgical Post-Take Ward Round Checklist Proforma: A Prompt for Improved DocumentationBritish journal of surgery · 2024
96. Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansformJournal of Neurology · 2024
97. Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA‐HCMJournal of the American Heart Association · 2024
98. Comprehensive Geriatric Assessment to Optimize the Management of Older Patients With Transthyretin Cardiac AmyloidosisJACC Advances · 2024
99. Safety and efficacy of aficamten in patients with non‐obstructive hypertrophic cardiomyopathy: A 36‐week analysis from FOREST‐HCMEuropean Journal of Heart Failure · 2024
100. Structure-Based Probe Reveals the Presence of Large Transthyretin Aggregates in Plasma of ATTR Amyloidosis PatientsJACC Basic to Translational Science · 2024